| Literature DB >> 35842721 |
Joseph Kwon1, Hazel Squires2, Matthew Franklin2, Tracey Young2.
Abstract
BACKGROUND: Falls impose significant health and economic burdens on community-dwelling older persons. Decision modelling can inform commissioning of alternative falls prevention strategies. Several methodological challenges arise when modelling public health interventions including community-based falls prevention. This study aims to conduct a systematic review (SR) to: systematically identify community-based falls prevention economic models; synthesise and critically appraise how the models handled key methodological challenges associated with public health modelling; and suggest areas for further methodological research.Entities:
Keywords: Decision modelling; Economic evaluation; Falls prevention; Geriatric public health
Year: 2022 PMID: 35842721 PMCID: PMC9287934 DOI: 10.1186/s12962-022-00367-y
Source DB: PubMed Journal: Cost Eff Resour Alloc ISSN: 1478-7547
Overview of included decision models for critical appraisal
| # | References | Target population | Type of analysis/perspective | Intervention [type] (# of forms) | Model type/time horizon |
|---|---|---|---|---|---|
| 1 | Agartioglu et al. [ | Fallers aged 65+ admitted to A&E | CEA/PS | HAM | DT/1 year |
| 2 | Albert et al. [ | CD aged 50+ (mean age 75.5) | CUA/PS | MF int. | DT/1 year |
| 3 | Alhambra-Borras et al. [ | CD aged 65+ at high falls risk or frail with no severe physical or cognitive limitation | CUA/PS | Exercise | Markov cohort/lifetime |
| 4 | Beard et al. [ | CD aged 60+ | CBA; ROI/PS; Soc | Intersectoral (MC) int.a | BDb/5 years |
| 5 | Boyd et al. [ | Aged 65+ | CUA/PS | Cataract surgery | Markov cohort/20 years |
| 6 | Carande-Kulis et al. [ | CD aged 65+ | ROI/US private health insurance | Exercise (2); MC int. | BD/1 year |
| 7 | CSP [ | CD aged 65+ | ROI/PS | FRS + exercise [PT] | DT/1 year |
| 8 | Church et al. [ | CD and residential care, aged 65+ | CEA; CUA/PS | Exercise (3); MC int.; MF int.; MRA; cataract surgery; Med. mod.; cardiac pacing | Markov cohort/10 years |
| 9 | Church et al. [ | CD aged 65+ | CEA; CUA/PS | Exercise (4); MC int.; MF int. (2); MRA; HAM; cataract surgery; Med. mod.; cardiac pacing | Markov cohort/lifetime |
| 10 | Comans et al. [ | CD aged 65+, falls history or gait/functional decline, cognitively intact | ROI/Soc | MF int. (2) | BD/1 year |
| 11 | Day et al. [ | CD, characteristics vary by interventionc | CEA/PS; Soc | Exercise (2); HAM; MF int.; Med. mod.; cardiac pacing | DT/1 year |
| 12 | Day et al. [ | CD aged 70+ | CEA/PS; Soc | Exercise [Tai Chi] | DT/1 year |
| 13 | Deverall et al. [ | CD aged 65+ | CUA/PS; Soc | Exercise (3) | Markov cohort/25 years |
| 14 | Eldridge et al. [ | Aged 65+, CD or nursing home | CUA/PS | FRS + MF int. or exercise | DT + Markov cohort/lifetime |
| 15 | Farag et al. [ | CD aged 65+, no falls history | CUA/PS | Non-specific int. | Markov cohort/lifetime |
| 16 | Franklin et al. [ | CD aged 65+ | CUA/PS | FRS + exercise (3) or HAM | DT + Markov cohort/2 years |
| 17 | Frick et al. [ | CD aged 65+ | CUA/US healthcare payerd | Exercise (2); HAM; MF int. (2); Med. mod.; Vit. D | BD/1 yeare |
| 18 | Hektoen et al. [ | CD women aged 80+ | CEA/Soc | Exercise | BD/1 year |
| 19 | Hiligsmann et al. [ | Aged 60+ with osteoporosis | CUA/Soc | Vit. D and calcium | Markov patient/lifetime |
| 20 | Hirst et al. [ | Women 75+ on pain medication | CUA/PS | Med. mod. | Markov patient/1 year |
| 21 | Honkanen et al. [ | Adults aged 65+, CD at baseline | CUA; ROI/Soc | Hip protectors | Markov cohort/lifetime |
| 22 | Howland et al. [ | CD aged 65+, fall admitted to A&E | ROI/US healthcare payerd | MC int | BD/1 year |
| 23 | Ippoliti et al. [ | CD aged 65+, mountainous areas | ROI/PS | MF int. | BD/3 years |
| 24 | Johansson et al. [ | CD aged 65+ | CUA/Soc | Intersectoral (MC) int.f | Markov cohort/lifetime |
| 25 | Lee et al. [ | CD aged 65–80, no falls history | CBA/PS | Vit. D [targeted vs. universal] | DT + Markov cohort/3 years |
| 26 | Ling et al. [ | CD aged 65+, falls history/risk factors | ROI/US healthcare payerd | HAM | BD/1 year |
| 27 | McLean et al. [ | CD aged 70+ | CEA; CUA/PS | Exercise | DT/18 months |
| 28 | Miller et al. [ | CD aged 50+ at high falls risk | ROI/US healthcared; Soc | MC int. | BD/2 years |
| 29 | Mori et al. [ | CD women 65+, no osteoporotic fracture | CUA/Soc | Exercise [alone or with bisphosphonate] | DT + Markov patient/lifetime |
| 30 | Moriarty et al. [ | CD aged 65, no adverse events from benzodiazepine/PPI | CUA/PS | Med. mod. | DT + Markov patient/35 years |
| 31 | Nshimyu-mukiza et al. [ | Women aged 40+ (subgroup 65+) | CEA; CUA/PS | Fracture risk screening + physical activity, Vit. D and calcium, and/or Osteoporosis screening and treatment | DT + Markov patient/lifetime |
| 32 | OMAS [ | CD aged 65+ | CEA; ROI/PS | Exercise; HAM; Vit. D and calcium; Med. mod.; gait-stabilizer | Markov cohort/lifetime |
| 33 | Pega et al. [ | CD aged 65+ | CUA/PS | HAM | Markov cohort/lifetime |
| 34 | Poole et al. [ | Aged 65+ | ROI/PS | Vit. D | BD/1 year |
| 35 | Poole et al. [ | CD aged 60+ | CUA; ROI/PS | Vit. D | Markov cohort/5 years |
| 36 | PHE [ | CD aged 65+ | CUA; ROI/PS | Exercise (3); HAM | DT/2 years |
| 37 | RCN [ | CD aged 60+ | CUA/PS | Exercise; MF int. | Markov cohort/lifetime |
| 38 | Sach et al. [ | Women 70+, bilateral cataracts | CEA; CUA/PS; Soc | Cataract surgery [first eye] | BD/lifetime extrapol.g |
| 39 | Sach et al. [ | Women 70+, second operable cataract | CUA/PS; Soc | Cataract surgery [second eye] | BD/lifetime extrapol.g |
| 40 | Smith et al. [ | Aged 65+ covered by GP and hospital | ROI/PS | FRS + MF int | Risk prediction/1 year |
| 41 | Tannenbaum et al. [ | CD aged 65+ and insomnia | CUA/PS | Med. mod.; CBT | Markov cohort/5 years |
| 42 | Turner et al. [ | CD aged 65+ chronic sedative use for insomnia | CUA/PS | Med. mod. | DT + Markov cohort/1 year |
| 43 | van der Velde et al. [ | CD geriatric outpatients with falls history | CEA/PS | Med. mod. | BD/1 yeare |
| 44 | Wilson et al. [ | CD aged 65+ | CUA/PS | HAM | Markov cohort/lifetime |
| 45 | Wu et al. [ | CD Medicare beneficiaries aged 65+ and falls history | CEA; ROI/PS; Soc | MF int. | BD/1 year |
| 46 | Zarca et al. [ | Aged 65+ without previous hip fracture | CEA; CUA/PS | Vit. D (targeted in two ways vs. universal) | DT + Markov patient/lifetime |
BD binary decision (model), CBA cost–benefit analysis, CBT cognitive behavioural therapy, CD community-dwelling, CEA cost-effectiveness analysis, CSP Chartered Society of Physiotherapy, CUA cost-utility analysis, DT decision tree, Exp. Expedited, FRS falls risk screening, HAM home assessment and modification, Int. intervention, Med. mod. medication modification, MC multiple-component, MF multifactorial, MRA multifactorial risk assessment only, OMAS Ontario Medical Advisory Secretariat, PHE Public Health England, PPI proton pump inhibitor, PS public sector, PT physiotherapy, RCN Royal College of Nursing, ROI return on investment analysis, Soc societal
aIncluded individually tailored education, HAM and exercise and public space safety improvement
bBinary decision models include two scenarios, with or without intervention, and no time-based cycles or probability trees
cCardiac pacing targeted population aged 50+ due to high falls risk. Other interventions targeted populations aged 65+
dThis would include public Medicare/aid, private health insurance and patients
e1-year horizon with lifetime costs of falls
fIncluded individually tailored education, group balance exercises, Tai Chi, other physical activities and HAM, neighbourhood hazard removal and housing reconstruction
g1-year trial outcomes are extrapolated over lifetime horizon
Non-health outcomes and societal intervention costs included in models
| Study labela | Non-health outcomes | Societal intervention costs | |||||
|---|---|---|---|---|---|---|---|
| Social wellbeing | Out-of-pocket expenditure | Productivity | Informal caregiver burden | Social cost | Private co-payment | Time opportunity costb | |
| Beard et al. (2006) | × | Not costed | |||||
| Carande-Kulis et al. (2015) | × | ||||||
| Comans et al. (2009) | × | ||||||
| Day et al. (2009, 2010) | × | ||||||
| Deverall et al. (2018) | × | Not costed | |||||
| Hektoen et al. (2009) | × | ||||||
| Hiligsmann et al. (2014) | × | ||||||
| Honkanen et al. (2006) | × | × | |||||
| Johansson et al. (2008) | × | × | × | × | |||
| Miller et al. (2011) | × | × | |||||
| Mori et al. (2017) | × | ||||||
| Sach et al. (2007, 2010) | × | × | |||||
| Wu et al. (2010) | Private insurance | ||||||
aSee Table 1 for study references
bTime opportunity cost of older participants and volunteers corresponding to productivity. No study incorporated time opportunity cost of informal caregivers attending intervention corresponding to informal caregiver burden; there is hence no dedicated column
Methods for assessing heterogeneity in decision models
| Study labela | Subgroup delineating variables | ||||||
|---|---|---|---|---|---|---|---|
| Age | Sex | Social | Falls history | Falls riskb | Chronic disease and Med. use | Physical capacity | |
| Alhambra-Borras et al. (2019) | SA | SA | |||||
| Boyd et al. (2020) | SA | SA | SA: ethnic | SA | |||
| Carande-Kulis et al. (2015) | TA | TA | |||||
| CSP (2016) | |||||||
| Day et al. (2009) | IN | IN | IN | IN | |||
| Deverall et al. (2018) | TA | SA | SA: ethnic | ||||
| Eldridge et al. (2005) | IN | IN | |||||
| Franklin et al. (2019) | TA | ||||||
| Hiligsmann et al. (2014) | TA | TA | |||||
| Hirst et al. (2016) | TA | ||||||
| Honkanen et al. (2006) | TA | TA | SA | ||||
| Ippoliti et al. (2018) | SA: region | ||||||
| Johansson et al. (2008) | SA | SA | |||||
| Lee et al. (2013) | SA | SA | TA | ||||
| McLean et al. (2015) | SA | ||||||
| Mori et al. (2017) | TA | TA | |||||
| Moriarty et al. (2019) | Separate modelsc | ||||||
| Nshimyumukiza et al. (2013) | TA | IN | |||||
| OMAS (2008) | SA; IN | IN | IN | IN | |||
| Pega et al. (2016) | TA | SA | SA: ethnic | TA | |||
| Poole et al. (2014) | SA; TA | SA | |||||
| Poole et al. (2015) | SA; TA | ||||||
| PHE (2018) | IN | ||||||
| Smith et al. (2016) | TA | ||||||
| Wilson et al. (2017) | TA | SA | SA: ethnic | TA | |||
| Wu et al. (2010) | SA | ||||||
| Zarca et al. (2014) | TA | SA | TA | ||||
CSP Chartered Society of Physiotherapy, ethnic. Ethnicity, Exo exogenous, Int. intervention, IN intervention need, Med. medication, OMAS Ontario Medical Advisory Secretariat, PHE Public Health England, RCN Royal College of Nursing, SA subgroup analysis, TA targeting analysis
aSee Table 1 for study references
bModels which evaluated a falls risk screening process and targeted intervention at high fall risk individuals in base case analysis but did not explore alternative non-targeted or differently targeted scenario(s) (e.g., CSP [96] and Franklin et al. [92]) were not marked as having performed TA
cThe study constructed separate models for non-steroidal anti-inflammatory drug, benzodiazepine and proton pump inhibitor users. The latter could be interpreted as intervention subgroups within the same target population
Time-variant falls risk factors and determinants of background health state utility and care cost progressions in non-binary models with horizons longer than 5 years
| Study labela | Time-variant falls risk factors | Backgroundb health/cost determinants | |||
|---|---|---|---|---|---|
| Age | Falls incidence | Other | Health state utility | Comorbidity care cost | |
| Cohort-level Markov modelsc | |||||
| Boyd et al. (2020) | Tunnel state?d | MA fall | Agee | Agee | |
| Church et al. (2011, 2012) | Tunnel state? | Any fall | Agef | ||
| Deverall et al. (2018) | Tunnel state? | MA fall | Agee | Agee | |
| Eldridge et al. (2005) | Tunnel state? | Fracture | FoF | Unclearf | Post-fractureg |
| Farag et al. (2015) | Tunnel state? | Any fall | Agef | ||
| Honkanen et al. (2006) | Tunnel state? | Hip fracture | FS | Agee; FS; LTC; post-hip fracture | FS; LTC |
| Johansson et al. (2008) | Tunnel state? | Hip fracture | Agee,f | Age | |
| Moriarty et al. (2019) | Tunnel state? | MA fall, Hip fracture | Agef | ||
| OMAS (2008) | Tunnel state? | MA fall | CEA | ||
| Pega et al. (2016) | Tunnel state? | MA fall | Agee | Agee | |
| RCN (2005) | Tunnel state? | Age | |||
| Wilson et al. (2017) | Tunnel state? | MA fall | Agee | Agee | |
| Individual-level Markov models | |||||
| Hiligsmann et al. (2014) | × | Post-hip and vertebral fractures | Post-hip fractureg | ||
| Mori et al. (2017) | × | Fracture | Osteoporosis | Age; post-hip and vertebral fractures | Post-hip fractureg |
| Nshimyumukiza et al. (2013) | × | Fracture | BMD | Post-hip and vertebral fractures | |
| Zarca et al. (2014) | × | Hip fracture | Vitamin D | Age; post-hip fracture | |
BMD bone mass density, CEA cost-effectiveness analysis, FoF fear of falling, FS functional status, LTC long-term care, MA fall fall requiring medical attention, OMAS Ontario Medical Advisory Secretariat, RCN Royal College of Nursing
aSee Table 1 for study references
bNot directed related to but indirectly influenced by falls/fractures: e.g., fatal fall influences lifetime comorbidity care costs
cAlhambra-Borras et al. [146] was excluded due to unclear description of the dynamic model states following intervention
dAge-based risk progression would require tunnel states but this was not mentioned or graphed, hence the question mark
eStratified by further time-invariant factors including sex and ethnicity
fUnclear whether events such as fracture and LTC admission incurred a one-off or permanent health utility loss
gIncorporated ongoing care costs for serious fractures, which are not technically comorbidity care costs since they are directly associated with fall/fracture in model; but they can be interpreted as such given their permanent nature
Summary of base case implementation levels, evidence source and outcomes in associated sensitivity analyses
| Study labela | Intervention | Base case implementation levelsb | Sensitivity analysis outcome | |||
|---|---|---|---|---|---|---|
| Initial access | Compliance | Sustainability (model time horizon) | Evidence source | |||
| Albert et al. (2016) | MF int. | Adherence: 78.6% Fidelity: 84.1% | Internal non-randomised | No analysis | ||
| Alhambra-Borras et al. (2019) | Exercise | Uptake: 39.6% | Internal quasi-experimental | No analysis | ||
| Beard et al. (2006) | MC (intersectoral) int. | Maint.: 5 years (of 5) | Internal quasi-experimental | No analysis | ||
| Church et al. (2011) | Multiple types | Maint.: 1 year (of 10) | Assumption | No analysis | ||
| Church et al. (2012) | Multiple types | Maint.: 1 year (of lifetime) | Assumption | No analysis | ||
| Comans et al. (2009) | MF int. (2 forms) | Uptake: as scenario | Assumption | ROI break-even | ||
| Day et al. (2009, 2010) | Multiple typesc | Uptake: 1.9% Tai Chi; 39.4% home exercise; 55.4% HAM; 55.4% MF int.; 18.9% Psychotropic med. withdrawal; 80.0% Cardiac pacing | Persistence: 61% home exercise Maint.: 1 year (of 2) home exercise; 1 year (of 5) cardiac pacing | External RCT | Falls and hospitalised falls averted; ICER (CEA) | |
| Deverall et al. (2018) | Group (commercial) exercise | Uptake: 52% | External RCT | Inc. cost; Inc. QALY; ICER (CUA) | ||
| Persistence: 80.5% uptake in year 2; 10% in year 10 | External RCTs and assumption | Same as uptake | ||||
| Maint.: permanent | External RCT | No analysis | ||||
| Home exercise | Uptake: 52% | External RCT | Inc. cost; Inc. QALY; ICER (CUA) | |||
| Persistence: 76.3% uptake in year 2; 10% in year 5 | External RCTs and assumption | Same as uptake | ||||
| Maint.: permanent | External RCT | No analysis | ||||
| Eldridge et al. (2005) | FRS + MF int. or exercise (prescribed or self-referred) | Uptake: 6.5% FRS; 50%/10% self-referred exercise for high-/low-risk persons | Internal survey | Proportion of total falls averted | ||
| Farag et al. (2015) | Non-specific intervention | Uptake: 50% | Assumption | ICER (CUA) | ||
| Franklin et al. (2019) | FRS + exercise (3 forms) or HAM | Uptake: 100% for those referred from FRS | Assumption | ICER (CUA) | ||
| Maint.: 1 year (of 2) | Assumption | No analysis | ||||
| Hiligsmann et al. (2014) | Vit D and calcium supplement | Maint.: 3 years (of lifetime) | Assumption | ICER (CUA) | ||
| Hirst et al. (2016) | Med. modification | Adherence: 29.4% of eligible days | External survey | Inc. cost; Inc. QALY; ICER (CUA) | ||
| Honkanen et al. (2006) | Hip protector | Adherence: 36% of daily hours | External survey | ICER (CUA) | ||
| Persistence: 50% discontinue after 1st year; discontinuation rate declines exponentially | External survey | ICER (CUA) | ||||
| Howland et al. (2015) | MC int. (lay-led) | Uptake: 50% | Assumption | Aggregate efficiency (ROI: net cost saving) | ||
| Fidelity: 100% refer | Assumption | No analysis | ||||
| Ippoliti et al. (2018) | MF int. | Uptake: 80% | Assumption | No analysis | ||
| Johansson et al. (2008) | MF int. | Maint.: 5 years (of lifetime) | Internal quasi-experiment | No analysis | ||
| Lee et al. (2013) | Vit D screening and supplement | Adherence: 80% | External RCT | No analysis | ||
| Miller et al. (2011) | MC int. (lay-led) | Adherence: 71.4% | Maint.: 1 year (of 2) | Assumption | No analysis | |
| Mori et al. (2017) | Home exercise | Uptake: 42% | External RCTs | No analysis | ||
| Maint.: 1 year (of lifetime) | Assumption | Inc. cost; Inc. QALY; ICER (CUA) | ||||
| Moriarty et al. (2019) | Med. modification (Benzodiazepine, PPI) | Adherence: 100% | Assumption | Inc. cost; Inc. QALY | ||
| Nshimyumukiza et al. (2013) | Fracture risk screening + physical activity, Vit D and calcium, and/or Osteoporosis screen and treatment | Uptake: 53% | External survey | ICER (CEA, CUA) | ||
| Maint.: permanent | Assumption | No analysis | ||||
| OMAS (2008) | Multiple types | Uptake: 57.0% exercise; 27.0% psychotropic med.; not specified for HAM, Vit D, Gait stabiliser | Adherence: 79.0% exercise; 75.7% HAM; 81.8% Vit D; 53.0% psychotropic med.; 80.0% Gait stabiliser | External RCTs and survey | No analysis | |
| Persistence: same as adherence | Assumption | No analysis | ||||
| Pega et al. (2016); Wilson et al. (2017) | HAM | Uptake: 89.0% | External RCT | Inc. cost; Inc. QALY; ICER (CUA) | ||
| Maint.: one-off, no renewal | Assumption | No analysis | ||||
| Poole et al. (2015) | Vit D supplement | Maint.: 5 years (of 5) | External RCTs | No analysis | ||
| PHE (2018) | Exercise (3 forms); HAM | Uptake: 20% | Maint.: 1 year (of 2) | Assumption | No analysis | |
| Turner et al. (2020) | Med. modification | Adoption: 66% of GPs received pharmacist advice; 79% met older persons for deprescribing | Uncleard | Inc. cost; Inc. QALY; ICER (CUA) | ||
| Uptake: 53% | External RCT | No analysis | ||||
| Wu et al. (2010) | MF int. | Uptake: 50% | External RCT and surveys | Aggregate efficiency (ROI: net cost saving); ICER (CEA) | ||
| Zarca et al. (2014) | Vit D screening and supplement | Adherence: 50%; 100% after fracture | External survey and assumption | ICER (CUA) | ||
| Maint.: permanent | Assumption | No analysis | ||||
CBT cognitive behavioural therapy, CEA cost-effectiveness analysis, CSP Chartered Society of Physiotherapy, CUA cost-utility analysis, FRID fall risk increasing drug, FRS falls risk screening, HAM home assessment and modification, ICER incremental cost-effectiveness ratio, Inc. incremental, Int. intervention, Maint. Maintenance, MC multiple-component, MF multifactorial, OMAS Ontario Medical Advisory Secretariat, PHE Public Health England, PPI proton pump inhibitor, QALY quality-adjusted life year, RCT randomised controlled trial, ROI return on investment
aSee Table 1 for study references
bSupply and demand dimensions to implementation levels are distinguished: uptake (demand) and adoption (supply) for initial access; adherence and fidelity for compliance; and persistence and maintenance for sustainability. See Additional file 1: Table S3 for the references concerning the terms used
cThe configuration is the same for Tai Chi in Day et al. [93]
dCites the model Moriarty et al. [120] which does not report the parameter estimates directly
Social and severity subgroups in models and cause(s) of reduced capacity to benefit
| Study labela | Subgroup delineatorb | Cause of reduced capacity to benefit | Note |
|---|---|---|---|
| Four BODE3 modelsc | Social: ethnicity (Maori vs. non-Maori) | Life expectancy differential | Also explores outcome differences across sex subgroups. Difficult to explore the double jeopardy problem due to homogenous intervention efficacy, cost and implementation level across subgroups |
| Eldridge et al. (2005) | Severity: fear of falling | Life expectancy differential | Fear of falling experienced by fallers and non-fallers and hence can be interpreted as frailty. Does not report subgroup results |
| Honkanen et al. (2006) | Severity: functional dependence | Double jeopardy; life expectancy differential | |
| Smith et al. (2016) | Severity: multivariate falls risk/frailtyd profile | No reduced capacity | Multivariate falls risk/frailty profile contained age, sex, all-cause secondary care use, fall and fracture history, chronic diseases and polypharmacy; all persons had same intervention efficacy, cost and implementation level |
BODE3 Burden of Disease Epidemiology, Equity & Cost-Effectiveness, HAM home assessment and modification
aSee Table 1 for study references
bIn identifying health severity subgroups, age, sex and individual fall/fracture risk factors (e.g., falls history, mobility impairment, bone mass density, vitamin D level, psychotropic medication use) were not interpreted as delineators. Studies that targeted specific patient groups within general older populations were excluded
cDeverall et al. [94], Boyd et al. [109], Wilson et al. [110] and Pega et al. [111] which were developed by the Burden of Disease Epidemiology, Equity and Cost-Effectiveness (BODE3) research group in New Zealand
dThe falls risk prediction tool included several indicators of generalised frailty (e.g., recurrent secondary care utilisations)
Suggestions for further methodological research and justification
| Methodological research suggestion | Justification |
|---|---|
| Challenge 1—Capturing non-health outcomes and societal intervention costs | |
| 1. Explore methods for consulting stakeholders on the appropriate perspective to take (e.g., public sector, societal) and the range of appropriate outcomes and costs, particularly under the societal perspective | Models operationalising the societal perspective were generally limited in terms of the range of societal outcomes and costs incorporated; see Table |
| 2. Explore methods and data sources for incorporating balanced sets of outcomes and intervention costs under the societal perspective | Balanced incorporation of non-health outcomes and societal intervention costs was achieved by only two of 15 models shown in Table |
| 3. Explore methods to account for sector-specific productive efficiencies under the societal perspective and to assess the relevance of established/possible cost-effectiveness thresholds [ | Accounting for the intersectoral differences in cost-effectiveness thresholds (i.e., productive efficiencies) would have changed the final decision in several models [ |
| Challenge 2—Considering heterogeneity and dynamic complexity | |
| 1. Explore methods and data sources for incorporating variables that depict geriatric health and falls risk variations within the same age and sex groups and over time, such as the continuous, multivariate frailty index [ | Models were limited in terms of incorporating subgroup delineators beyond age and sex (Table |
| 2. Explore the impact on intervention rankings of the choice in the main decision metric between cost-per-unit ratio and aggregate outcome [ | Several models evaluated interventions targeting heterogeneously sized subgroups then compared the resulting ICERs only. This may have introduced misleading interpretations of economic outcomes: see the last paragraph of “ |
| 3. Explore methods and data sources for characterising the heterogeneity in intervention efficacy, cost and implementation level | Heterogeneities in intervention efficacy and cost were characterised by only one model each (“ |
| 4. Explore the feasibility of developing individual-level simulation to capture the age-related progression in falls risk and other dynamic patterns in geriatric health aspects (e.g., progressions in comorbidity care costs) | Tunnel states were not described for the 13 cohort-level Markov models in Table |
| 5. Explore methods for modelling: (i) periodic falls risk screening to allow dynamic variation in the proactive intervention pathway (5); and (ii) access to reactive pathway after a serious falls incidence | No model incorporated repeated falls/fracture risk screening to reassess the need for proactive intervention access. Only one model shifted individuals to the reactive pathway once a fracture occurred (“ |
| 6. Explore methods for modelling incoming cohorts of newly eligible persons to characterise the dynamic target population size and capacity implications | Models mentioned the non-incorporation of incoming cohorts as a limitation that underestimated the total intervention costs and benefits (“ |
| Challenge 3—Considering theories of human behaviour and implementation | |
| 1. Explore methods and data sources for incorporating individual- and social-level variables that influence health behaviour and intervention supply/demand | No model directly parameterised psychological and social causal mechanisms based on individual and social behavioural theories (“ |
| 2. Explore methods for distinguishing between supply- and demand-side implementation factors and evidence sources for long-term sustainability of interventions | Only Turner et al. [ |
| 3. Explore the feasibility of conducting value of implementation analyses as alternative scenarios of implementation strategies with aggregate monetary outcomes to estimate the willingness to pay | Models often assessed the variations in implementation levels under DSA (i.e., to assess parameter uncertainty) rather than scenario analysis (“ |
| 4. Explore the feasibility of developing models that explicitly incorporate capacity constraints, such as discrete events simulation [ | No model considered the capacity or budget implications of their interventions. This resulted in misleading outcomes; an example is given in “ |
| Challenge 4—Considering issues of equity | |
| 1. Explore methods for consulting stakeholders to identify relevant social and health severity delineators | Table |
| 2. Explore methods and data sources for modelling causal mechanisms behind vulnerable subgroups’ reduced capacity to benefit | Models in Table |
| 3. Explore methods for equity analysis that assesses the equity-efficiency trade-off under alternative intervention strategies, such as DCEA [ | No model evaluated alternative strategies that prioritised the vulnerable subgroups and then estimated the efficiency-equity trade-off (“ |
DCEA distributional cost-effectiveness analysis, DSA deterministic sensitivity analysis, ICER incremental cost-effectiveness ratio, INMB incremental net monetary benefit, PHMC public health modelling challenge, ROI return on investment